Biologics & Cell/Gene Therapy CDMOs
CDMOs manufacturing biologic drugs and advanced therapies.
Market snapshot
These figures describe Contract Development & Manufacturing (CDMO) (4.9.3), the segment that Biologics & Cell/Gene Therapy CDMOs sits within — not Biologics & Cell/Gene Therapy CDMOs on its own.
Within pharmaceutical manufacturing (NAICS 325412); CDMOs are not separately identified, so the segment is not separately sized by the Census Bureau.
Business model & economics
Revenue model
Development and manufacturing fees on contracted capacity
Key economics
- Recurring revenue
- High
- EBITDA margin
- 20–30%
- Capex intensity
- High
multi-year manufacturing contracts
Characteristics
- Fast-growing outsourcing of complex manufacturing.
- Biologics and sterile injectables drive demand.
- Capacity, resilience, and reshoring concerns.
Geographic concentration
CDMO capacity concentrates in the pharma manufacturing belt — New Jersey and Massachusetts — with a growing Colorado bioprocessing cluster.
U.S. Census Bureau — 2022 County Business Patterns (establishments by state), NAICS 325412. Concentration shown by location quotient.
M&A deal context
Who’s acquiring
- CDMO majors & strategics
- Pharma-services consolidators
- PE-backed manufacturing platforms
What’s driving deals
- Acquisition of biologics and advanced-modality capacity.
- Biologics and sterile-injectable demand.
- Supply-chain resilience and reshoring.
Find Biologics & Cell/Gene Therapy CDMOs acquisition targets
Search Acquisera’s index for companies classified under Biologics & Cell/Gene Therapy CDMOs (4.9.3.2) and build a targeted deal pipeline.
Search companies